Novel use of a cardiac septal occluder to treat a chronic recalcitrant bariatric fistula after Roux-en-Y gastric bypass

Although considered the gold standard for the treatment of obesity, bariatric surgeries are not free of complications. Fistulas occur after Roux-en-Y gastric bypass (RYGB) and sleeve gastrectomy in up to 8.3% and 7% of patients, respectively [1, 2]. We describe the first report of the off-label use of the cardiac septal occluder (AMPLATZER Septal Occluder; Abbott, St. Paul, Minnesota, USA) for the treatment of a chronic bariatric fistula (▶Video 1).

A 33-year-old man with grade II obesity underwent RYGB. After 1 week, the patient was admitted with abdominal pain and fever. Computed tomography scan diagnosed a gastric pouch leak associated with intra-abdominal collections (▶Fig. 1). Emergency surgery was indicated, a peri-gastric collection associated with a gastric pouch leak was confirmed, and placement of two abdominal drains was performed, followed by admission to the intensive care unit. After 25 days, the drain output was 300 mL/day, and an upper endoscopy showed a 20-mm leak in the gastric pouch in the topography of the superior staple line, just below the esophagogastric junction (▶Fig. 2). An esophageal fully covered metal stent (Hanaro, 16 cm × 22 mm; Micro Tech Co. Ltd., Anseong-Si, South Korea) was placed (▶Fig. 3). The stent was fixed with the Shin technique to avoid migration [3]. After the stent placement, the drain output decreased to 30 mL/day. The stent was removed 4 weeks later because of patient intolerance. During the endoscopy, a chronic fistula (15 mm) with the external drain tube inside the orifice was observed. The drain was removed under direct endoscopic vision, until the endoscope was advanced to...
The skin. The fistula tract was noted to be fully epithelized. As this chronic fistula remained unresponsive, placement of a cardiac septal occluder was performed (▶ Video 1, ▶ Fig. 4) [4, 5]. After 15 days, the cutaneous ostium was closed completely (▶ Fig. 5). The patient remained asymptomatic at the 3-month follow-up.

Endoscopy_UCTN_Code_TTT_1AO_2AI

Competing interests

Dr. Thompson reports personal fees from Boston Scientific, personal fees from Olympus, outside the submitted work.

The authors

Diogo Turiani Hourneaux de Moura1, 2, Igor Braga Ribeiro1, Mateus Pereira Funari1, Alberto Baptista1, Christopher C. Thompson2, Eduardo Guimarães Hourneaux de Moura1

1 Gastrointestinal Endoscopy Unit, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
2 Division of Gastroenterology, Harvard Medical School, Brigham and Women’s Hospital, Boston, Massachusetts, United States
3 Department of Endoscopy, Hospital de Clínicas Caracas, San Bernardino, Venezuela

Corresponding author

Igor Braga Ribeiro, MD
Gastrointestinal Endoscopy Unit, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Av. Dr Enéas de Carvalho Aguiar, 225, 6º andar, bloco 3, Cerqueira Cesar 05403-010, São Paulo, Brazil
Fax: +55-11-26616467
igorbraga1@gmail.com

References


Bibliography

DOI https://doi.org/10.1055/a-0842-6287
Published online: 21.2.2019
Endoscopy 2019; 51: E111–E112
© Georg Thieme Verlag KG Stuttgart · New York
ISSN 0013-726X

This document was downloaded for personal use only. Unauthorized distribution is strictly prohibited.